Trial Profile
A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Dexanabinol (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors e-Therapeutics
- 03 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 08 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 08 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.